Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3263985 | 1.00 | CTSD (0.69) | CTSDBACE1 | |
| SCHEMBL3261066 | 1.00 | CTSD (0.69) | CTSDBACE1 | |
| SCHEMBL3259588 | 1.00 | CTSD (0.69) | CTSDBACE1 | |
| SCHEMBL4494198 | 0.91 | CTSD (0.57) | CTSDBACE1 | |
| SCHEMBL3260528 | 0.88 | CTSD (0.68) | CTSDBACE1 | |
| SCHEMBL3184974 | 0.87 | CTSD (0.72) | CTSDBACE1 | |
| SCHEMBL3188658 | 0.87 | CTSD (0.75) | CTSDBACE1 | |
| SCHEMBL3187708 | 0.83 | CTSD (0.58) | CTSDBACE1 | |
| SCHEMBL3177680 | 0.81 | CTSD (1.00) | CTSDBACE1 | |
| SCHEMBL3197158 | 0.81 | CTSD (1.00) | CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | NOVARTIS AG | 2010-01-28 | — | — | US | disclosed |
| US-7612055-B2 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-03-29 | — | — | US | disclosed |
| EP-1682521-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | RPS11, MRPL21, RPS4Y1 | CTSD 789/4885BACE1 406/4885 |
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | RPS11, MRPL21, RPS4Y1 | CTSD 789/4885BACE1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.